Articles by Stephanie Sutton - BioPharm International



Articles by Stephanie Sutton

EU Court Dismisses AstraZeneca Appeal

Dec 10, 2012

The Court of Justice of the European Union has dismissed an appeal by AstraZeneca concerning a 2005 decision that found the company guilty of abusing its dominant position in the marketplace.

EMA Publishes Plan to Deal with Supply Shortages

Dec 3, 2012

The European Medicines Agency has published a plan to help Europe?s regulatory network prevent, mitigate and manage shortages of important medicines following manufacturing problems.

Europe Considers Black Box Warnings

Nov 26, 2012

The European Commission (EC) is seeking to introduce a black symbol to identify medicines that are subject to additional monitoring.

A Golden Era for Pharma in 2020

Nov 21, 2012

More favourable conditions for the pharmaceutical industry, including a "golden era of renewed productivity and prosperity" have been forecast in a new report from analyst firm PricewaterhouseCoopers (PwC).

EFCG Calls for Inspections of API Manufacturers

Nov 14, 2012

The European Fine Chemicals Group has proposed that mandatory inspections be introduced for all global API manufacturers wishing to supply the European Union market.

EC Approves Europe's First Gene Therapy

Nov 6, 2012

The European Commission (EC) has issued final approval for Europe’s first gene therapy; a treatment for a rare genetic disorder that currently has no other treatment options.

Dr. Reddy's Announces Plans to Acquire OctoPlus for EUR 27 Million ($35.7 Million)

Oct 22, 2012

Dr Reddy's is planning to acquire the specialty injectable company OctoPlus for approximately EUR27.4 million ($35.7 million) in cash to strengthen its technological capabilities in drug delivery.

GSK Encourages Open Innovation and R&D

Oct 15, 2012

GlaxoSmithKline (GSK) has outlined the measures it is taking as part of a new open innovation approach to R&D, including opening up its tuberculosis compound library, investing in its open laboratory in Spain, and sharing detailed clinical trial data with researchers.

Takeda to Acquire LigoCyte Pharmaceuticals

Oct 8, 2012

Takeda's US subsidiary, Takeda America Holdings, is to acquire the vaccine specialist company LigoCyte Pharmaceuticals for an upfront payment of $60 million in a move intended to bolster and expand the company’s vaccine business.



Click here